University of Texas - MD Anderson Cancer Center

University of Texas - MD Anderson Cancer Center

University of Texas - MD Anderson Cancer Center

Date Founded



1515 Holcombe Boulevard,Suite 137,Houston, TX 77001

Charitable Causes

Higher Education & Universities
Hospitals & Health Centers


IT Consulting & Services
Medical Support Services
Hospitals & Patient Services

Company Description

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Contact Data
Trying to get in touch with decision makers at University of Texas - MD Anderson Cancer Center? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees




Chief Executive Officer

Executive Director Clinical Operations

Executive Director

Executive Director, Immunotherapy Platform

Executive Director, Quantitative Imaging Analysis Core, Division of Diagnostic Imaging

Executive Director of Clinical Operations

Board of Directors

Chairman, Department of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine at University of Texas - MD Anderson Cancer Center

President & Chief Executive Officer, International Bank of Commerce-Laredo, Texas at International Bancshares Corp.

Director, Global Hematology-Oncology Pediatric Excellence, Texas Children's Cancer & Hematology Centers at Texas Children's Hospital

Former Non-Executive Chairman-Texas Operations at JPMorgan Chase & Co.

Former Chief Executive Officer at LyondellBasell Industries NV

Chief Commercial Officer at FuelCell Energy, Inc.

Vice Chairman & Co-Founder at Twinlab Holdings, Inc.

Distinguished Alumni
Michael Connor is now Co-Founder at Scarology
Jack Hu is now Former Research Analyst at Prudential Equity Group LLC
Paths to University of Texas - MD Anderson Cancer Center
Potential Connections via
Relationship Science
University of Texas - MD Anderson Cancer Center
Recent Transactions
Details Hidden

University of Texas - MD Anderson Cancer Center purchases Bellicum Pharmaceuticals, Inc. /Houston Facility from Bellicum Pharmaceuticals Inc.

Advisors & Consultants

Executive Managing Director-National Healthcare Advisory Services Healthcare Advisory Services at Transwestern Commercial Services LLC


Chairman at Grenzebach Glier & Associates, Inc.


Senior Vice President, Analytics & Executive Director, ALF at Grenzebach Glier & Associates, Inc.


Our goal, at Myriad, is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, we are focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties. Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care. Today, Myriad continues to build on this strong tradition. We are working to expand our reach by introducing new genetic tests and molecular diagnostic tests for a number of diseases. We also are focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Details Hidden

OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.

Harvard Bioscience, Inc. Industrial Machinery & Manufacturing | Holliston, MA

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Jaggaer LLC IT Consulting & Services | Morrisville, NC

Jaggaer LLC provides cloud-based business automation solutions for spend management. It offers spend analysis, savings management, sourcing, supplier management, accounts payable, contract lifecycle management, and inventory management solutions. The company was founded in 1995 and is headquartered in Morrisville, NC.

StageZero Life Sciences Ltd. Hospitals & Patient Services | Richmond Hill, Canada

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Richmond Hill, Canada.

Awards & Honors
Rank #286
The Chronicle of Philanthropy - Philanthropy 400
Rank #110
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by University of Texas - MD Anderson Cancer Center. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of University of Texas - MD Anderson Cancer Center's profile does not indicate a business or promotional relationship of any kind between RelSci and University of Texas - MD Anderson Cancer Center.